Jonas Oldgren
YOU?
Author Swipe
View article: Prevalence and prediction of masked uncontrolled hypertension in patients recently hospitalized for myocardial infarction
Prevalence and prediction of masked uncontrolled hypertension in patients recently hospitalized for myocardial infarction Open
Aims To study the prevalence of masked uncontrolled hypertension (MUCH) in patients recently hospitalized for myocardial infarction, and to develop machine learning-based prediction models identifying MUCH. Methods and results Ambulatory b…
View article: Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study
Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study Open
BACKGROUND: The clinical use of risk scores to guide treatment decisions and improve clinical outcomes has rarely been prospectively evaluated. This study aimed to evaluate whether a biomarker-based ABC-AF risk score–guided multidimensiona…
View article: Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial
Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial Open
Background Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type‐2 diabetes (T2DM) in the DAPA‐MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic…
View article: Associations between physical activity and CVD-related metabolomic and proteomic biomarkers
Associations between physical activity and CVD-related metabolomic and proteomic biomarkers Open
Aim Habitual physical activity (PA) affects metabolism and homeostasis in various tissues and organs. However, detailed knowledge of associations between PA and cardiovascular disease (CVD) risk markers is limited. We sought to identify as…
View article: Alcohol Intake and Cardiovascular Outcomes in Patients With Atrial Fibrillation: <scp>RE</scp>‐<scp>LY AF</scp> Registry Analysis
Alcohol Intake and Cardiovascular Outcomes in Patients With Atrial Fibrillation: <span>RE</span>‐<span>LY AF</span> Registry Analysis Open
Background Alcohol intake increases recurrence of atrial fibrillation (AF), but its relationship with cardiovascular outcomes is less well characterized. We aimed to study the association between different levels of alcohol intake and card…
View article: Prevalence of microspirometry-detected chronic obstructive pulmonary disease in two European cohorts of patients hospitalised for acute myocardial infarction: a cross-sectional study
Prevalence of microspirometry-detected chronic obstructive pulmonary disease in two European cohorts of patients hospitalised for acute myocardial infarction: a cross-sectional study Open
Objectives To establish the prevalence of clinically significant chronic obstructive pulmonary disease (COPD) and relevant characteristics in individuals with a significant smoking history who are hospitalised for acute myocardial infarcti…
View article: Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use Open
Importance In patients with atrial fibrillation (AF), oral anticoagulants (OACs) reduce the risk of stroke. Objective To investigate if patients with less prior OAC exposure respond differently to a new OAC than patients with more OAC expo…
View article: Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation
Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation Open
Background Cardiac biomarkers improve risk prediction in patients with atrial fibrillation (AF). We recently demonstrated that the NFL (neuron‐specific protein neurofilament light chain) was associated with ischemic stroke in patients with…
View article: Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy
Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy Open
Background Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial. Purpose Ca…
View article: Social differences in subclinical coronary artery atherosclerosis in Sweden
Social differences in subclinical coronary artery atherosclerosis in Sweden Open
Most data indicate an inverse relation between socioeconomic status and clinically manifest coronary heart disease that is only partly explained by modifiable cardiovascular risk factors. Few population-based studies have investigated soci…
View article: Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy
Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy Open
Background Dapagliflozin improved cardiometabolic outcomes compared with placebo following acute myocardial infarction (MI) in participants without prior diabetes mellitus (DM) or chronic heart failure (HF) in the DAPA-MI trial. Purpose To…
View article: The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design Open
AIMS: Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expens…
View article: The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction ( <scp>SPIRRIT</scp> ‐ <scp>HFpEF</scp> ): Rationale and design
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction ( <span>SPIRRIT</span> ‐ <span>HFpEF</span> ): Rationale and design Open
Aims Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensi…
View article: Asundexian versus Apixaban in Patients with Atrial Fibrillation
Asundexian versus Apixaban in Patients with Atrial Fibrillation Open
Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the…
View article: Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study
Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study Open
Aims Men are more likely to suffer a myocardial infarction than women, but population-based studies on sex differences in imaging-detected atherosclerosis are lacking. The aims were to assess sex differences in the prevalence of imaging-de…
View article: SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in People With Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled, Positron Emission Tomography Study
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in People With Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled, Positron Emission Tomography Study Open
Objective: The aim of this study was to investigate the impact of the sodium-glucose transporter 2 inhibitor dapagliflozin on tissue fatty acid (FA) uptake in skeletal muscle, the brain, small intestine, and subcutaneous and visceral adipo…
View article: Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial Open
Background BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measur…
View article: Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure
Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure Open
Journal Article Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure Get access Stefan James, Stefan James Department of medical Sciences and Uppsala Clinical Resaech Center, Uppsala Univeristy, 7518…
View article: Repeated measurement of the novel atrial biomarker BMP10 improves risk stratification in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial
Repeated measurement of the novel atrial biomarker BMP10 improves risk stratification in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial Open
Background Atrial fibrillation (AF) increases the risk of stroke, heart failure, and death. Biomarkers provide important prognostic information about these complications in AF. Recently, bone morphogenic protein 10 (BMP10), a protein mainl…
View article: Neurofilament light chain (NFL) - a neuron-specific plasma biomarker for evaluating risk of ischemic cerebral events in atrial fibrillation
Neurofilament light chain (NFL) - a neuron-specific plasma biomarker for evaluating risk of ischemic cerebral events in atrial fibrillation Open
Background A history of ischemic stroke is one of the strongest risk factors for future stroke in patients with atrial fibrillation (AF). Circulating biomarkers specific for the brain may be used to detect overt and covert cerebral ischemi…